Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

May 10, 2016

Primary Completion Date

September 10, 2018

Study Completion Date

December 21, 2018

Conditions
Irritable MoodHuntington's Disease
Interventions
DRUG

SRX246

DRUG

Placebo

Trial Locations (22)

10032

Columbia University Medical Center, New York Presbyterian Hospital, New York

11733

SUNY Stony Brook Clinical Research Center, Department of Neurology, East Setauket

14618

University of Rochester Medical Center, Rochester

15213

University of Pittsburgh Medical Center, Department of Neurology, Pittsburgh

22908

University of Virginia Health System, Department of Neurology, Charlottesville

30329

Emory University, Atlanta

33136

University of Miami, Miller School of Medicine, Jackson Behavioral Health Hospital, Miami

35233

University of Alabama, Birmingham

37232

Vanderbilt Clinical Research Center, Nashville

43221

Ohio State University, Wexner Medical Center, Department of Neurology, Columbus

45219

University Medical Arts Building, Cincinnati

60611

Northwestern Out-Patient Neurology Clinic, Chicago

63110

Washington University School of Medicine, St Louis

66160

University of Kansas Medical Center, Kansas City

75390

UT Southwestern Medical Center, Dallas

80045

University of Colorado Hospital Translational Research Center, Aurora

84108

University of Utah, Department of Neurology, Salt Lake City

90095

UCLA, Neurology Clinic, Los Angeles

95817

UC Davis Medical Center, Department of Neurology, CTSC Clinical Research Center, Sacramento

97239

Oregon Health and Science University, Portland

98122

Swedish Neuroscience Institute, Seattle

02129

Massachusetts General Hospital, Charlestown

Sponsors
All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

collaborator

NeuroNEXT Network

OTHER

lead

Azevan Pharmaceuticals

INDUSTRY

NCT02507284 - Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease | Biotech Hunter | Biotech Hunter